WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Ivor Royston Biography and Net Worth

CEO of Viracta Therapeutics

Dr. Royston has served as President, Chief Executive Officer, and Director of Viracta since 2015. From 1990 to 2017, Dr. Royston was a Managing Partner of Forward Ventures, a life science venture capital firm. From 1990 to 2000, Dr. Royston also held the position of Chief Executive Officer of the Sidney Kimmel Cancer Center. Prior to that, Dr. Royston was the Director of Clinical Immunology at University of California, San Diego Cancer Center. Dr. Royston was the co-founder of Hybritech, Inc., which developed the PSA test for prostate cancer; and the co-founder of IDEC Corporation, which developed Rituxan, the first approved monoclonal antibody therapy for lymphoma, and which subsequently merged with Biogen to form Biogen Idec, now Biogen. Dr. Royston currently serves on the board of directors of Biocept, Inc. (NASDAQ:BIOC). Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University.

What is Ivor Royston's net worth?: The estimated net worth of Ivor Royston is at least $128,681.70 as of August 26th, 2022. Dr. Royston owns 612,770 shares of Viracta Therapeutics stock worth more than $128,682 as of December 21st. This net worth approximation does not reflect any other assets that Dr. Royston may own. Learn More about Ivor Royston's net worth.
How do I contact Ivor Royston?: The corporate mailing address for Dr. Royston and other Viracta Therapeutics executives is 2533 S. COAST HWY. 101 SUITE 210, CARDIFF CA, 92007. Viracta Therapeutics can also be reached via phone at (858) 400-8470 and via email at [email protected]. Learn More on Ivor Royston's contact information.
Has Ivor Royston been buying or selling shares of Viracta Therapeutics?: Ivor Royston has not been actively trading shares of Viracta Therapeutics in the last ninety days. Most recently, Ivor Royston sold 13,379 shares of the business's stock in a transaction on Friday, August 26th. The shares were sold at an average price of $4.01, for a transaction totalling $53,649.79. Following the completion of the sale, the chief executive officer now directly owns 612,770 shares of the company's stock, valued at $2,457,207.70. Learn More on Ivor Royston's trading history.
Who are Viracta Therapeutics' active insiders?: Viracta Therapeutics' insider roster includes Daniel Chevallard (CFO), Lisa Rojkjaer (Insider), and Ivor Royston (CEO). Learn More on Viracta Therapeutics' active insiders.
Are insiders buying or selling shares of Viracta Therapeutics?: In the last year, insiders at the sold shares 1 times. They sold a total of 3,405 shares worth more than $2,485.65. The most recent insider tranaction occured on February, 27th when CFO Daniel R Chevallard sold 3,405 shares worth more than $2,485.65. Insiders at Viracta Therapeutics own 10.7% of the company. Learn More about insider trades at Viracta Therapeutics.
Information on this page was last updated on 2/27/2024.

Ivor Royston Insider Trading History at Viracta Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/26/2022	Sell	13,379	$4.01	$53,649.79	612,770
5/26/2022	Sell	13,162	$1.90	$25,007.80	600,930
2/28/2022	Sell	14,635	$2.78	$40,685.30
11/29/2021	Sell	15,833	$4.82	$76,315.06
11/26/2021	Sell	11,914	$4.80	$57,187.20
11/15/2021	Buy	8,000	$5.56	$44,480.00

Ivor Royston Buying and Selling Activity at Viracta Therapeutics

Viracta Therapeutics Company Overview

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. Its lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. The company's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. Its product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

Today's Range

Now: $0.21

$0.21

$0.26

50 Day Range

MA: $0.19

$0.14

$0.26

2 Week Range

Now: $0.21

$0.13

$1.31

Volume

1,701,261 shs

Average Volume

775,484 shs

Market Capitalization

$8.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67